Current treatment status-Undergoing active treatment-Progressive despite treatment Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment-Progressive despite treatment Posts on Medivizor

Second-line tyrosine kinase treatment in patients with chronic myeloid leukemia who have failed first-line treatment

Posted by on Apr 3, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate second-line tyrosine kinase inhibitor (TKI) treatment in patients with chronic-phase chronic myeloid leukemia (CP-CML) who had failed first-line TKI treatment.  This study concluded that these patients have good outcomes with second-line TKI treatment.   Some background Tyrosine kinase...

Read More

Reviewing treatment options for patients with recurrent classical Hodgkin’s lymphoma

Posted by on Mar 16, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This article reviews treatment options for patients with classical Hodgkin's lymphoma (cHL) that came back (relapsed) after chemotherapy. This study found that targeted therapies are becoming more prevalent and that patient outcomes have improved. Some background cHL is a cancer of white blood cells called lymphocytes....

Read More

Have outcomes improved for patients with Hodgkin’s lymphoma who relapse after a stem cell transplant?

Posted by on Mar 16, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the long-term outcomes of patients with classical Hodgkin’s lymphoma (cHL) that came back after an autologous stem cell transplant (autoSCT). This study found that advancements in treatment have helped improve survival outcomes for patients. Some background Chemotherapy is usually the first-line...

Read More

The comparison of outcomes of two salvage therapies in patients with relapsed or unresponsive acute myeloid leukemia

Posted by on Mar 4, 2020 in Leukemia | 0 comments

In a nutshell The study evaluated the effectiveness of two salvage therapies – mitoxantrone (Novantrone), etoposide (Etopophos), and cytarabine (Cytosar-U) also known as MEC and cladribine (Leustatin), cytarabine, filgrastim (Neupogen), and mitoxantrone also known as CLAG-M, for treating relapsed/refractory acute myeloid leukemia...

Read More

The effects of blinatumomab in patients with relapsed or unresponsive acute lymphoblastic leukemia in outside of clinical trials

Posted by on Feb 24, 2020 in Leukemia | 0 comments

In a nutshell The study evaluated the safety and effectiveness of blinatumomab (Blincyto) in patients with relapsed or unresponsive B-acute lymphoblastic leukemia (B-ALL) outside of clinical trials. The authors found that blinatumomab was safe and effective to treat such patients in real-world medical practice. Some background Relapsed...

Read More

Evaluating the R-BAC regimen for patients with MCL that stops responding to TKI therapy

Posted by on Feb 22, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the outcomes of the R-BAC (rituximab, bendamustine, cytarabine) regimen for patients with relapsed or unresponsive mantle cell lymphoma (MCL). This study concluded that R-BAC was effective for these patients. Some background MCL is a rare but aggressive type of non-Hodgkin’s lymphoma (NHL). After initial...

Read More

Evaluating stem cell transplant outcomes for patients classical Hodgkin’s lymphoma

Posted by on Feb 16, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study looked at the outcomes of autologous stem cell transplantation (ASCT) to treat recurrent classical Hodgkin’s lymphoma (cHL). This study concluded that ASCT is effective, with patients who responded after the transplant having the best outcomes. Some background cHL is usually treated with chemotherapy and...

Read More

Evaluating BEGEV chemotherapy before a stem cell transplant for hard-to-treat Hodgkin lymphoma

Posted by on Feb 5, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness of BEGEV chemotherapy for patients with relapsed or unresponsive Hodgkin lymphoma (HL) before a stem cell transplant. The authors concluded that this regimen was safe and effective for these patients. Some background Chemotherapy, followed by a stem cell transplant (SCT), remains the standard of...

Read More